Literature DB >> 11920596

Persistent human papillomavirus infection and smoking increase risk of failure of treatment of cervical intraepithelial neoplasia (CIN).

Nabil Nathan Acladious1, Chrostopher Sutton, Debbi Mandal, Rami Hopkins, Magid Zaklama, Henery Kitchener.   

Abstract

Women with abnormal smears have an increased risk of developing cervical cancer. During the 8 years following conservative treatment of cervical intraepithelial neoplasia (CIN), their risk of invasive cervical cancer is about 5 times greater than that of the general population. Human papillomavirus (HPV) has been associated with the natural history of both CIN and cervical cancer. To date, there have been no published reports on the predictive value of HPV testing in the treatment outcome of CIN. A prospective, multi-center, cohort study was conducted on women in the Northwest of England who were attending for treatment of CIN. They were asked to complete a questionnaire, which included a detailed smoking history. Pre- and post-treatment HPV testing was performed on cervical biopsies and cervical swab, being taken with the first follow-up smear at 6 months. A nested case-control analysis was performed, cases being defined as women who developed CIN within the 2 years of treatment and controls being sampled from those who did not experience treatment failure within 2 years. Multiple conditional logistic regression is used to study the factors associated with treatment failure of CIN. The cohort included 958 women of whom 77 (8%) experienced treatment failure (cases). Two controls were matched to each case (154). Smoking status was significantly associated with CIN treatment failure(p= 0.0013). Current smokers had a 3-fold increased risk of treatment failure of CIN as compared to non-smokers (95% CI 1.65 to 5.91). Five hundred twenty-five women underwent HPV sampling following treatment, of whom 47 (8.9%) developed further CIN. Post-treatment positive HPV testing was found to be strongly associated with treatment failure of CIN (OR 23.3; 95% CI 3.15-172.1). In 11/45 cases with negative smear at first follow-up, the HPV test was positive. The combination of both HPV and cytology in the first follow-up visit predicted treatment failure in 72% of the cases. Cigarette smoking is a factor, which, independently of HPV infection, influences the treatment outcome of CIN. Smokers and those who are HPV positive during follow-up appear to require longer, more intensive follow-up. HPV testing requires careful consideration as part of routine follow-up protocol following treatment of CIN. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11920596     DOI: 10.1002/ijc.10080

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

1.  Long-term risk of recurrent cervical human papillomavirus infection and precancer and cancer following excisional treatment.

Authors:  Aimée R Kreimer; Mark Schiffman; Rolando Herrero; Allan Hildesheim; Paula González; Robert D Burk; Carolina Porras; Mark E Sherman; Franklin Demuth; Li Cheung; Concepción Bratti; Ana Cecilia Rodríguez
Journal:  Int J Cancer       Date:  2011-08-30       Impact factor: 7.396

2.  Evaluation of a commercialized in situ hybridization assay for detecting human papillomavirus DNA in tissue specimens from patients with cervical intraepithelial neoplasia and cervical carcinoma.

Authors:  Ming Guo; Yun Gong; Michael Deavers; Elvio G Silva; Yee Jee Jan; David E Cogdell; Rajyalashmi Luthra; E Lin; Hung Cheng Lai; Wei Zhang; Nour Sneige
Journal:  J Clin Microbiol       Date:  2007-10-31       Impact factor: 5.948

Review 3.  Posttreatment human papillomavirus testing for recurrent cervical intraepithelial neoplasia: a systematic review.

Authors:  Benjamin K S Chan; Joy Melnikow; Christina A Slee; Rose Arellanes; George F Sawaya
Journal:  Am J Obstet Gynecol       Date:  2009-01-24       Impact factor: 8.661

4.  Brief smoking cessation advice from practice nurses during routine cervical smear tests appointments: a cluster randomised controlled trial assessing feasibility, acceptability and potential effectiveness.

Authors:  S Hall; E Reid; O C Ukoumunne; J Weinman; T M Marteau
Journal:  Br J Cancer       Date:  2007-04-10       Impact factor: 7.640

5.  The differential expression of OCT4 isoforms in cervical carcinoma.

Authors:  Shao-Wen Li; Xiao-Ling Wu; Chun-Li Dong; Xiu-Ying Xie; Jin-Fang Wu; Xin Zhang
Journal:  PLoS One       Date:  2015-03-27       Impact factor: 3.240

6.  Comparison of Expectant and Excisional/Ablative Management of Cervical Intraepithelial Neoplasia Grade 2 (CIN2) in the Era of HPV Testing.

Authors:  Kevin Dominique Tjandraprawira; Adeola Olaitan; Aviva Petrie; Nafisa Wilkinson; Adam N Rosenthal
Journal:  Obstet Gynecol Int       Date:  2022-03-24

7.  Predictors of treatment failure for adenocarcinoma in situ of the uterine cervix: Up to 14 years of recorded follow-up.

Authors:  Karen Belkić; Sonia Andersson; Susanna Alder; Miriam Mints; David Megyessi
Journal:  Oncol Lett       Date:  2022-08-25       Impact factor: 3.111

8.  Smoking is an independent risk factor for oncogenic human papillomavirus (HPV) infections but not for high-grade CIN.

Authors:  Kari Syrjänen; Irena Shabalova; Nicolay Petrovichev; Vladimir Kozachenko; Tatjana Zakharova; Julia Pajanidi; Jurij Podistov; Galina Chemeris; Larisa Sozaeva; Elena Lipova; Irena Tsidaeva; Olga Ivanchenko; Alla Pshepurko; Sergej Zakharenko; Raisa Nerovjna; Ludmila Kljukina; Oksana Erokhina; Marina Branovskaja; Maritta Nikitina; Valerija Grunberga; Alexandr Grunberg; Anna Juschenko; Rosa Santopietro; Marcella Cintorino; Piero Tosi; Stina Syrjänen
Journal:  Eur J Epidemiol       Date:  2007-09-08       Impact factor: 12.434

9.  Molecular Detection and Typing of Human Papillomaviruses in Paraffin-Embedded Cervical Cancer and Pre-Cancer Tissue Specimens.

Authors:  Pezhman Mahmoodi; Hossein Motamedi; Masoud Reza Seyfi Abad Shapouri; Mahjabin Bahrami Shehni; Mohammad Kargar
Journal:  Iran J Cancer Prev       Date:  2016-02-22

10.  Prevalence and genotypes of human papilloma virus infection in CIN3 in Beijing, China.

Authors:  Xuan-Yu Zhao; Wei-Min Kong; Si-Meng Jiao; Dan Song; Jiao Chen; Ruo-Tian Shang
Journal:  Transl Cancer Res       Date:  2020-03       Impact factor: 1.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.